Recent advances in breast cancer cell line research

Author:

Sharma Manika P12,Shukla Supriya12,Misra Gauri12ORCID

Affiliation:

1. Molecular Diagnostics and COVID‐19 Kit Testing Laboratory National Institute of Biologicals (Ministry of Health and Family Welfare) Noida India

2. Academy of Scientific and Innovative Research (AcSIR) Ghaziabad India

Abstract

AbstractBreast cancer, a formidable global health challenge, needs continuous translational research to understand the complexity of mechanisms and improve therapeutic and diagnostic strategies. Breast cancer cell lines are of paramount importance as they significantly contribute to the initial stage of research to understand cancer biology. This review provides insights into targeted therapies and immunotherapies that have emerged using in vitro models and microbiome analysis. It focuses on therapeutic development using cell lines and the limitations of tumor heterogeneity and microenvironment. We explore the evolving landscape of breast cancer cell lines from two‐dimensional (2‐D) cultures to patient‐derived xenograft (PDX) models advancing both fundamental and translational research. Patient‐derived xenografts, cell line‐derived xenografts (CDX), three‐dimensional (3‐D) cultures, organoids, and circulating tumor cells (CTC) models provide promising alternatives that capture the intricacies of the tumor microenvironment. This review bridges the gap between traditional cell lines and newer developments exploring the therapeutic and diagnostic advancements and needs for cell lines to expedite the progress in breast cancer research and treatment.

Funder

Indian Council of Medical Research

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference89 articles.

1. WHO.Breast Cancer Details.2023. Accessed July 2023.https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2. Globocan.TGCO.Estimated Age‐Standardized Incidence Rates (World) in 2020 India Both Sexes All Ages(excl. NMSC). 2020. Accessed July 2023.https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf

3. MASTL: A novel therapeutic target for Cancer Malignancy

4. Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation

5. Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3